Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):487-497. doi: 10.1080/17425255.2019.1622679. Epub 2019 May 29.


Introduction: Platinum-drugs (Cisplatin, Carboplatin, Oxaliplatin) are widely used in Medical Oncology departments to treat common neoplasms whose survival has greatly increased in the last few years. Thus, there is a growing population of cancer survivors who were treated with them and whose Quality of Life can be impaired by neurological late toxicities. Areas covered: Essential clinical information of natural history, predisposing factors, assessment issues and lacks in treatment for peripheral neurotoxicity are here reported. An overview of preclinical pathogenetic observations is also given to drive future drug discovery. Expert opinion: To unravel needs and lacks for platinum-induced neurotoxicity a great effort is still to be done. A coordinated and combined effort of clinical and preclinical researchers is required. The newborn multidisciplinary Toxic Neuropathy Consortium - Special Interest Group of the Peripheral Nerve Society - seems a virtuous alliance that might find answers to meet clinical and scientific needs in this field.

Keywords: Platinum-drugs; Quality of Life; animal models; cancer survivors; peripheral neurotoxicity; translational medicine.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Cancer Survivors
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neurotoxicity Syndromes / etiology*
  • Oxaliplatin / administration & dosage
  • Oxaliplatin / adverse effects
  • Quality of Life


  • Antineoplastic Agents
  • Oxaliplatin
  • Carboplatin
  • Cisplatin